First Generic GLP-1 Injection OK'd for Weight Loss

FDA approves first generic GLP-1 indicated for weight loss

The FDA has approved the first generic GLP-1 specifically indicated for weight loss, according to a press release from Teva Pharmaceuticals. As Healio previously reported, Teva Pharmaceuticals launched the first generic GLP-1 in June 2024. That medication, which was a generic version of liraglutide 1.8 mg (Victoza, Novo Nordisk), was indicated to improve glycemic control in patients aged 10

First Generic GLP-1 Injection OK'd for Weight Loss

(MedPage Today) -- The FDA approved the first-ever generic form of a GLP-1 receptor agonist specifically indicated for weight loss, Teva Pharmaceuticals announced Thursday. The generic form of liraglutide (Saxenda) is indicated for adults with...

Pharma Pulse: CDC Director Pushback, Persistent Drug Shortages, and FDA Clears First Generic GLP-1 for Weight Loss

This episode of Pharma Pulse covers Susan Monarez’s rejection of White House efforts to remove her as CDC director, new analysis on how long-lasting drug shortages expose systemic supply chain weaknesses, and the FDA’s approval of the first generic liraglutide for weight management.

FDA Approves Generic Version of Liraglutide Injection, a GLP-1 for Weight Loss

Generic liraglutide injection is the first GLP-1 indicated for weight loss.

FDA Approves First Generic GLP-1 Liraglutide for Weight Loss

Liraglutide is the first glucagon-like peptide-1 to have a generic equivalent for both type 2 diabetes and obesity indications.

Teva Launches First Generic GLP-1 Drug for Obesity

Liraglutide, a generic of Saxenda, is approved to treat adults and adolescents who are obese or overweight.